NantHealth, Inc. (NASDAQ:NH) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, NH is expected to report 3Q20 loss of $ 0.06 per share from revenue of $ 18.16 million.
For the full year, analysts anticipate top line of $ 72.85 million, while looking forward to loss of $ 0.24 per share bottom line.
Previous Quarter Performance
NantHealth, Inc. unveiled loss for the second quarter of $ 0.07 per share, from the revenue of $ 17.59 million. The quarterly revenues shrunk 31.53 percent compared with the same quarter last year. Wall street analysts are predicting, NH to report 2Q20 loss of $ 0.05 per share from revenue of $ 18.10 million. The bottom line results missed street analysts by $ 0.02 or 40 percent, at the same time, top line results fell short of analysts by $ 0.51 million or 2.82 percent.
Stock Performance
Shares of NantHealth, Inc. traded up $ 0.00 or 0.00 percent on Wednesday, reaching $ 2.14 with volume of 68.30 thousand shares. NantHealth, Inc. has traded high as $ 2.19 and has cracked $ 2.08 on the downward trend
The closing price of $ 2.14, representing a 229.23 % increase from the 52 week low of $ 0.65 and a 66.51 % decrease over the 52 week high of $ 6.39.
The company has a market capital of $ 278.71 million and is part of the Technology sector and Health Information Services industry.
NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.